Ponatinib and vorinostat increase cell growth inhibition and induce apoptosis in BCR-ABL-expressing cells.

<p>(A) Cells were cultured at a concentration of 8×10⁴/mL in the presence or absence of ponatinib and/or vorinostat for 72 h. The percentage of proliferating cells was evaluated, as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0089080#s2" target="_blank">Materials and Methods</a>. (B) K562 or Ba/F3 T315I cells were treated with ponatinib and/or vorinostat for 24 h, and total extracts were examined by immunoblot analysis with anti-phospho ABL, Crk-L, γH2A.X, cleaved caspase 3, PARP, acetyl histone H4, and tubulin antibodies. (C) Primary samples were cultured in the presence or absence of ponatinib and/or vorinostat. The number of living cells was calculated. *<i>P</i><0.05 or **<i>P</i><0.01, ponatinib and vorinostat treatment versus ponatinib treatment. (D) Primary cells were treated with ponatinib and/or vorinostat at the indicated concentrations for 24 h. The cells were examined by immunoblot analysis.